These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37151179)

  • 1. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
    Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
    Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
    Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
    Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
    Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
    Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
    J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    Sechi E; Zekeridou A
    J Thorac Oncol; 2021 Mar; 16(3):381-394. PubMed ID: 33188910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
    Zivelonghi C; Zekeridou A
    J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review.
    Dinoto A; Mantovani E; Ferrari S; Mariotto S; Tamburin S
    Eur J Neurol; 2023 Mar; 30(3):774-781. PubMed ID: 36325694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
    Nassar AH; El Zarif T; Khalid AB; Rahme S; Zhong C; Kwak L; Salame M; Farhat EB; Freeman D; El-Am E; Ravishankar A; Ahmad B; Nana FA; Kaldas D; Naqash AR; Sharon E; LeBoeuf NR; Cortellini A; Malgeri A; Gupta S; Al-Hader A; Sparks JA; Linnoila J; Hamnvik OR; Mouhieddine TH; Marron T; Parikh K; McKay RR; Dilling T; Choueiri TK; Adib E; Najem E; Kim SY; Sonpavde G
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38448038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
    Farina A; Villagrán-García M; Fourier A; Pinto AL; Chorfa F; Timestit N; Alberto T; Aupy J; Benaiteau M; Birzu C; Campetella L; Cotton F; Dalle S; Delaruelle CF; Dumez P; Germi R; Le Maréchal M; Maillet D; Marignier R; Pegat A; Psimaras D; Rafiq M; Picard G; Desestret V; Quadrio I; Honnorat J; Joubert B
    Lancet Reg Health Eur; 2024 Sep; 44():101011. PubMed ID: 39170102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
    Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
    Müller-Jensen L; Zierold S; Versluis JM; Boehmerle W; Huehnchen P; Endres M; Mohr R; Compter A; Blank CU; Hagenacker T; Meier F; Reinhardt L; Gesierich A; Salzmann M; Hassel JC; Ugurel S; Zimmer L; Banks P; Spain L; Soon JA; Enokida T; Tahara M; Kähler KC; Seggewiss-Bernhardt R; Harvey C; Long GV; Schöberl F; von Baumgarten L; Hundsberger T; Schlaak M; French LE; Knauss S; Heinzerling LM
    Eur J Cancer; 2022 Nov; 175():224-235. PubMed ID: 36155116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system adverse events of immune checkpoint inhibitors.
    Farina A; Villagrán-García M; Vogrig A; Joubert B
    Curr Opin Neurol; 2024 Jun; 37(3):345-352. PubMed ID: 38483130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
    Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.